SGLT2 inhibitors may also benefit patients without HF who have experienced MI [26] as they seem to reduce in-hospital arrhythmias [36] and contrast-induced acute kidney injury (CI-AKI) [37] in the post-MI setting. The gene discussed is SLC5A2; the disease is hydrops fetalis.